Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2003 Sep;58(9):752–756. doi: 10.1136/thorax.58.9.752

Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I

M Spruit 1, R Gosselink 1, T Troosters 1, A Kasran 1, G Gayan-Ramirez 1, P Bogaerts 1, R Bouillon 1, M Decramer 1
PMCID: PMC1746817  PMID: 12947130

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is often associated with peripheral muscle weakness, which is caused by several factors. Acute exacerbations may contribute, but their impact on muscle force remains unclear. Correlations between peripheral muscle force and inflammatory and anabolic markers have never been studied in COPD. The effect of an acute exacerbation on quadriceps peak torque (QPT) was therefore studied in hospitalised patients, and the aforementioned correlations were examined in hospitalised and in stable patients.

Methods: Lung function, respiratory and peripheral muscle force, and inflammatory and anabolic markers were assessed in hospitalised patients on days 3 and 8 of the hospital admission and 90 days later. The results on day 3 (n=34) were compared with those in clinically stable outpatients (n=13) and sedentary healthy elderly subjects (n=10).

Results: Hospitalised patients had lowest mean (SD) QPT (66 (22)% predicted) and highest median (IQR) levels of systemic interleukin-8 (CXCL8, 6.1 (4.5 to 8.3) pg/ml). Insulin-like growth factor I (IGF-I) tended to be higher in healthy elderly subjects (p=0.09). QPT declined between days 3 and 8 in hospital (mean -5% predicted (95% CI -22 to 8)) and partially recovered 90 days after admission to hospital (mean 6% predicted (95% CI -1 to 23)). QPT was negatively correlated with CXCL8 and positively correlated with IGF-I and lung transfer factor in hospitalised and in stable patients.

Conclusions: Peripheral muscle weakness is enhanced during an acute exacerbation of COPD. CXCL8 and IGF-I may be involved in the development of peripheral muscle weakness in hospitalised and in stable patients with COPD.

Full Text

The Full Text of this article is available as a PDF (157.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anthonisen N. R., Manfreda J., Warren C. P., Hershfield E. S., Harding G. K., Nelson N. A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987 Feb;106(2):196–204. doi: 10.7326/0003-4819-106-2-196. [DOI] [PubMed] [Google Scholar]
  2. Barnes P. J. Potential novel therapies for chronic obstructive pulmonary disease. Novartis Found Symp. 2001;234:255–272. [PubMed] [Google Scholar]
  3. Bernard S., LeBlanc P., Whittom F., Carrier G., Jobin J., Belleau R., Maltais F. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 Aug;158(2):629–634. doi: 10.1164/ajrccm.158.2.9711023. [DOI] [PubMed] [Google Scholar]
  4. Black L. F., Hyatt R. E. Maximal respiratory pressures: normal values and relationship to age and sex. Am Rev Respir Dis. 1969 May;99(5):696–702. doi: 10.1164/arrd.1969.99.5.696. [DOI] [PubMed] [Google Scholar]
  5. Cappola A. R., Bandeen-Roche K., Wand G. S., Volpato S., Fried L. P. Association of IGF-I levels with muscle strength and mobility in older women. J Clin Endocrinol Metab. 2001 Sep;86(9):4139–4146. doi: 10.1210/jcem.86.9.7868. [DOI] [PubMed] [Google Scholar]
  6. Carrol E. D., Thomson A. P. J., Mobbs K. J., Fraser W. D., Sills J. A., Hart C. A. Myositis in children with meningococcal disease: a role for tumour necrosis factor-alpha and interleukin-8? J Infect. 2002 Jan;44(1):17–21. doi: 10.1053/jinf.2001.0923. [DOI] [PubMed] [Google Scholar]
  7. Cicoira M., Bolger A. P., Doehner W., Rauchhaus M., Davos C., Sharma R., Al-Nasser F. O., Coats A. J., Anker S. D. High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. Cytokine. 2001 Jul 21;15(2):80–86. doi: 10.1006/cyto.2001.0918. [DOI] [PubMed] [Google Scholar]
  8. Cook E. B., Stahl J. L., Lowe L., Chen R., Morgan E., Wilson J., Varro R., Chan A., Graziano F. M., Barney N. P. Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics. J Immunol Methods. 2001 Aug 1;254(1-2):109–118. doi: 10.1016/s0022-1759(01)00407-0. [DOI] [PubMed] [Google Scholar]
  9. Creutzberg E. C., Wouters E. F., Vanderhoven-Augustin I. M., Dentener M. A., Schols A. M. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1239–1245. doi: 10.1164/ajrccm.162.4.9912016. [DOI] [PubMed] [Google Scholar]
  10. Decramer M., Gosselink R., Troosters T., Verschueren M., Evers G. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J. 1997 Feb;10(2):417–423. doi: 10.1183/09031936.97.10020417. [DOI] [PubMed] [Google Scholar]
  11. Decramer M., Lacquet L. M., Fagard R., Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med. 1994 Jul;150(1):11–16. doi: 10.1164/ajrccm.150.1.8025735. [DOI] [PubMed] [Google Scholar]
  12. Decramer M., de Bock V., Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 1):1958–1964. doi: 10.1164/ajrccm.153.6.8665061. [DOI] [PubMed] [Google Scholar]
  13. Dentener M. A., Creutzberg E. C., Schols A. M., Mantovani A., van't Veer C., Buurman W. A., Wouters E. F. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax. 2001 Sep;56(9):721–726. doi: 10.1136/thorax.56.9.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Dev D., Wallace E., Sankaran R., Cunniffe J., Govan J. R., Wathen C. G., Emmanuel F. X. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med. 1998 Apr;92(4):664–667. doi: 10.1016/s0954-6111(98)90515-7. [DOI] [PubMed] [Google Scholar]
  15. Eid A. A., Ionescu A. A., Nixon L. S., Lewis-Jenkins V., Matthews S. B., Griffiths T. L., Shale D. J. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 1):1414–1418. doi: 10.1164/ajrccm.164.8.2008109. [DOI] [PubMed] [Google Scholar]
  16. Ekberg-Jansson A., Andersson B., Bake B., Boijsen M., Enanden I., Rosengren A., Skoogh B. E., Tylén U., Venge P., Löfdahl C. G. Neutrophil-associated activation markers in healthy smokers relates to a fall in DL(CO) and to emphysematous changes on high resolution CT. Respir Med. 2001 May;95(5):363–373. doi: 10.1053/rmed.2001.1050. [DOI] [PubMed] [Google Scholar]
  17. Flick D. A., Gifford G. E. Pharmacokinetics of murine tumor necrosis factor. J Immunopharmacol. 1986;8(1):89–97. doi: 10.3109/08923978609031087. [DOI] [PubMed] [Google Scholar]
  18. García-Martínez C., Agell N., Llovera M., López-Soriano F. J., Argilés J. M. Tumour necrosis factor-alpha increases the ubiquitinization of rat skeletal muscle proteins. FEBS Lett. 1993 Jun 1;323(3):211–214. doi: 10.1016/0014-5793(93)81341-v. [DOI] [PubMed] [Google Scholar]
  19. Gosselink R., Troosters T., Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med. 1996 Mar;153(3):976–980. doi: 10.1164/ajrccm.153.3.8630582. [DOI] [PubMed] [Google Scholar]
  20. Hambrecht Rainer, Schulze Paul Christian, Gielen Stephan, Linke Axel, Möbius-Winkler Sven, Yu Jiangtao, Kratzsch J J. ürgen, Baldauf Gerhard, Busse Martin W., Schubert Andreas. Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. J Am Coll Cardiol. 2002 Apr 3;39(7):1175–1181. doi: 10.1016/s0735-1097(02)01736-9. [DOI] [PubMed] [Google Scholar]
  21. Iannuzzi-Sucich Michele, Prestwood Karen M., Kenny Anne M. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. J Gerontol A Biol Sci Med Sci. 2002 Dec;57(12):M772–M777. doi: 10.1093/gerona/57.12.m772. [DOI] [PubMed] [Google Scholar]
  22. Li Y. P., Schwartz R. J., Waddell I. D., Holloway B. R., Reid M. B. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J. 1998 Jul;12(10):871–880. doi: 10.1096/fasebj.12.10.971. [DOI] [PubMed] [Google Scholar]
  23. Marcell T. J., Harman S. M., Urban R. J., Metz D. D., Rodgers B. D., Blackman M. R. Comparison of GH, IGF-I, and testosterone with mRNA of receptors and myostatin in skeletal muscle in older men. Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1159–E1164. doi: 10.1152/ajpendo.2001.281.6.E1159. [DOI] [PubMed] [Google Scholar]
  24. Marquis Karine, Debigaré Richard, Lacasse Yves, LeBlanc Pierre, Jobin Jean, Carrier Guy, Maltais François. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002 Sep 15;166(6):809–813. doi: 10.1164/rccm.2107031. [DOI] [PubMed] [Google Scholar]
  25. Mathiowetz V., Kashman N., Volland G., Weber K., Dowe M., Rogers S. Grip and pinch strength: normative data for adults. Arch Phys Med Rehabil. 1985 Feb;66(2):69–74. [PubMed] [Google Scholar]
  26. Müller E. A. Influence of training and of inactivity on muscle strength. Arch Phys Med Rehabil. 1970 Aug;51(8):449–462. [PubMed] [Google Scholar]
  27. Niebauer J., Pflaum C. D., Clark A. L., Strasburger C. J., Hooper J., Poole-Wilson P. A., Coats A. J., Anker S. D. Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J Am Coll Cardiol. 1998 Aug;32(2):393–397. doi: 10.1016/s0735-1097(98)00226-5. [DOI] [PubMed] [Google Scholar]
  28. Polkey M. I., Kyroussis D., Hamnegard C. H., Mills G. H., Green M., Moxham J. Quadriceps strength and fatigue assessed by magnetic stimulation of the femoral nerve in man. Muscle Nerve. 1996 May;19(5):549–555. doi: 10.1002/(SICI)1097-4598(199605)19:5<549::AID-MUS1>3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  29. Quanjer P. H., Tammeling G. J., Cotes J. E., Pedersen O. F., Peslin R., Yernault J. C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993 Mar;16:5–40. [PubMed] [Google Scholar]
  30. Rahman I., Skwarska E., MacNee W. Attenuation of oxidant/antioxidant imbalance during treatment of exacerbations of chronic obstructive pulmonary disease. Thorax. 1997 Jun;52(6):565–568. doi: 10.1136/thx.52.6.565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Reid Michael B., Lännergren Jan, Westerblad Håkan. Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments. Am J Respir Crit Care Med. 2002 Aug 15;166(4):479–484. doi: 10.1164/rccm.2202005. [DOI] [PubMed] [Google Scholar]
  32. Schols A. M., Buurman W. A., Staal van den Brekel A. J., Dentener M. A., Wouters E. F. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996 Aug;51(8):819–824. doi: 10.1136/thx.51.8.819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Seemungal T. A., Donaldson G. C., Bhowmik A., Jeffries D. J., Wedzicha J. A. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000 May;161(5):1608–1613. doi: 10.1164/ajrccm.161.5.9908022. [DOI] [PubMed] [Google Scholar]
  34. Seemungal T. A., Donaldson G. C., Paul E. A., Bestall J. C., Jeffries D. J., Wedzicha J. A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1418–1422. doi: 10.1164/ajrccm.157.5.9709032. [DOI] [PubMed] [Google Scholar]
  35. Spruit M. A., Gosselink R., Troosters T., De Paepe K., Decramer M. Resistance versus endurance training in patients with COPD and peripheral muscle weakness. Eur Respir J. 2002 Jun;19(6):1072–1078. doi: 10.1183/09031936.02.00287102. [DOI] [PubMed] [Google Scholar]
  36. Thompson W. H., Nielson C. P., Carvalho P., Charan N. B., Crowley J. J. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):407–412. doi: 10.1164/ajrccm.154.2.8756814. [DOI] [PubMed] [Google Scholar]
  37. Todorov P., Cariuk P., McDevitt T., Coles B., Fearon K., Tisdale M. Characterization of a cancer cachectic factor. Nature. 1996 Feb 22;379(6567):739–742. doi: 10.1038/379739a0. [DOI] [PubMed] [Google Scholar]
  38. Vermeeren M. A., Schols A. M., Wouters E. F. Effects of an acute exacerbation on nutritional and metabolic profile of patients with COPD. Eur Respir J. 1997 Oct;10(10):2264–2269. doi: 10.1183/09031936.97.10102264. [DOI] [PubMed] [Google Scholar]
  39. Visser Marjolein, Pahor Marco, Taaffe Dennis R., Goodpaster Bret H., Simonsick Eleanor M., Newman Anne B., Nevitt Michael, Harris Tamara B. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci. 2002 May;57(5):M326–M332. doi: 10.1093/gerona/57.5.m326. [DOI] [PubMed] [Google Scholar]
  40. Watchorn T. M., Waddell I., Dowidar N., Ross J. A. Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-(kappa)B and STAT3. FASEB J. 2001 Jan 19;15(3):562–564. doi: 10.1096/fj.00-0534fje. [DOI] [PubMed] [Google Scholar]
  41. Wedzicha J. A., Seemungal T. A., MacCallum P. K., Paul E. A., Donaldson G. C., Bhowmik A., Jeffries D. J., Meade T. W. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost. 2000 Aug;84(2):210–215. [PubMed] [Google Scholar]
  42. Willaert W., Daenen M., Bomans P., Verleden G., Decramer M. What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Eur Respir J. 2002 May;19(5):928–935. doi: 10.1183/09031936.02.00268702. [DOI] [PubMed] [Google Scholar]
  43. de Godoy I., Donahoe M., Calhoun W. J., Mancino J., Rogers R. M. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med. 1996 Feb;153(2):633–637. doi: 10.1164/ajrccm.153.2.8564110. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES